Highlights Lithium Universe Limited has raised AU$463,500 through a share purchase plan (SPP). LU7 aims to strengthen its position in the lithium space, backed by access to prime mining regions in Canada and Australia. Proceeds from the SPP will propel LU7's Québec Lithium Processing Hub (QLPH) strategy, targeting the North American battery material supply. Lithium Universe Limited (ASX: LU7) has successfully closed an SPP with applications for 23,175,000 fully paid shares, raising a total of AU$463,500. The SPP, announced on 13 March 2024, was closed on 10 April 2024. LU7 aims to solidify ..read more

Highlights Bile tract cancer expansion study opens after the completion of the high dose cohort in the MAST trial. This new trial aims to enrol 10 patients with bile tract cancers, specifically cholangiocarcinoma. Interim findings from the MAST trial have revealed encouraging responses in gastrointestinal cancers, especially in cholangiocarcinoma. The clearance of the fifth cohort in the intratumoural (IT) arm of the VAXINIA monotherapy trial marks a significant milestone. Imugene Limited (ASX: IMU) has commenced enrolment for the expansion study focusing on cholangiocarcinoma patients. Th ..read more

Macro Metals, an iron ore company, has officially announced its decision to not proceed with the planned acquisition of an 85% interest in the lithium rights associated with the Aurora Lithium Project. This acquisition was originally intended to be carried out from Aurora Energy Metals. The decision by Macro Metals to abandon this acquisition signifies a strategic shift or a change in priorities for the company. It suggests that after evaluating the deal or considering other factors, Macro Metals has determined that pursuing this acquisition may not align with its current business objectives ..read more

Imugene has said that enrolment has opened for its expansion study in bile tract cancer patients, having completed the fifth, high dose cohort evaluating its cancer-killing virus CF33-hNIS. The clinical stage immunooncology company said that the expansion trial is expected to enrol 10 patients with bile tract cancers ..read more

According to the latest data released by the Australian Bureau of Statistics (ABS), there has been a notable decrease in the amount of food purchased by Australians during the 2022-23 period compared to the previous year. Specifically, Australians bought approximately 3.9% less food during this timeframe. In terms of quantity, this reduction translates to a daily decrease of 63 grams of food per person. Additionally, the energy intake has also seen a decline, with a reduction of 337 kilojoules (kJ) per day per individual. This data sheds light on changing consumption patterns and habits among ..read more

DroneShield has reported its March quarterly update with revenues for the 1Q24 rising 10 fold to $16.4 million, compared to the same period last year. 1Q24 SaaS revenues also doubled to $561k against the same prior corresponding period ..read more

The Australian share market is expected to open lower. DroneShield reported revenues for the 1Q24 rose 10 fold to $16.4 million. Imugene opens enrolment for its expansion study in bile tract cancer patients. Macro Metals confirms it will not proceed with the acquisition of the Aurora Lithium Project ASX at Breakfast TICKER 150424.docx ..read more

South32 Ltd (ASX: S32) has been making significant strides in the stock market, with its shares surging by over 1% per day for the past 13 consecutive trading days. Trading at AU$3.29 on Friday, the mining giant's shares have displayed notable resilience, marking a 15.22% increase over the aforementioned trading period. Just over two weeks ago, on 26 March, South32 shares closed at AU$2.89, hovering close to its 52-week low of AU$2.75 reached on 21 February. Investors who capitalised on the opportunity to invest AU$10,000 in South32 shares 13 days ago would now find their investment valued at ..read more

For many investors, the primary goal of engaging in the stock market is to attain remarkable returns. While not every stock delivers exceptional performance, successful investments can yield substantial gains. Consider, for instance, the remarkable ascent of Pro Medicus Limited (ASX: PME) shares, which have surged by an astounding 536% over the past five years. Such remarkable growth underscores the potential for substantial returns through long-term investing, serving as a testament to the rewards of patience and strategic investment. Furthermore, shareholders of Pro Medicus have reason to re ..read more

Australia's Boral (ASX: BLD) has advised investors to consider accepting a takeover bid from its largest shareholder, Seven Group Holdings (ASX: SVW), amounting to up to AU$1.5 billion ($980.70 million). This recommendation follows negotiations that resulted in an augmentation of the cash portion of the deal. Controlled by billionaire Kerry Stokes and his family, Seven Group has increased its ownership in the building products maker from 71.6% to 78.8% since initially expressing interest in acquiring full control of Boral in February. The updated proposal from Seven Group now includes 0.1116 S ..read more